RTOG 94-13 is a phase III study designed to determine the appropriatetreatment volume and the optimal way to combine radiation and
RTOG 94-13 is a phase III study designed to determine the appropriatetreatment volume and the optimal way to combine radiation andtotal androgen suppression for prostate cancer patients who areat greater risk of local/systemic failure.
Patients who have localized adenocarcinoma of the prostate andhave an elevated prostate-specific antigen (PSA) level are eligiblefor the trial, reports Mack Roach, MD, chair of the study. Theaccrual goal is 1,200 patients.
Patients are being randomized to one of four arms:
In both arms 3 and 4, flutamide and goserelin are being givenfor 4 months once radiation therapy is completed.
"This study allows us to answer the critical question ofwhether whole pelvis irradiation plus a boost improves the progressionfree-survival of these patients," says Dr. Roach.
"It also allows us to test the hypothesis that flutamideand Zoladex are more effective if they are administered beforeand during radiation therapy rather than after radiation treatments,"he adds.